Michael Rickels, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1346272630
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,192 of the $65,295 with a category attached, or 72.3%. Vertex accounts for 85.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $23,650, 4.9 times the $4,875 reported in 2020. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $1231.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$56K
- Zealand Pharma US, Inc.$7K
- Sanofi US Services Inc.$1K
- Novo Nordisk$900
- Zealand Pharma A/s$704
- Abbott$21
Across 26 payments — averaging $20,786 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$267K
- Xeris Pharmaceuticals, Inc.$150K
- Tandem Diabetes Care, Inc.$123K
- Medtronic$591
What the payments were for
- Consulting fees$47,19272%
- Speaking & faculty fees$7,63412%
- Travel & lodging$9,26914%
- Food & beverage$1,1992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 36 | $55,967 |
| Zealand Pharma US, Inc. | 12 | $6,672 |
| Sanofi US Services Inc. | 1 | $1,031 |
| Novo Nordisk | 1 | $900 |
| Zealand Pharma A/s | 2 | $704 |
| Abbott | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEGALOGUE$6,512
How this compares
$65,295 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $52,204 |
| Novolog FlexpenInsulin Aspart | 19 | $3,588 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,150 |
| Metformin Hcl ErMetformin Hcl | 30 | $898 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $656 |
| Ezetimibe | 12 | $637 |
| Atorvastatin Calcium | 23 | $433 |
| Gabapentin | 13 | $247 |
| Rosuvastatin Calcium | 11 | $186 |
| Levothyroxine Sodium | 19 | $152 |
| Metformin Hcl | 19 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $900 | $52,20435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
- Vijay BahlPittsburgh$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.